QMPSB

QMPSB is an arylsulfonamide-based synthetic cannabinoid that has been sold as a designer drug.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

QMPSB is an arylsulfonamide-based synthetic cannabinoid that has been sold as a designer drug. QMPSB was first discovered by Nathalie Lambeng and colleagues in 2007. It acts as a full agonist of the CB 1 receptor and CB 2 receptor with K i values of 3 nM and 4 nM, respectively.

Many related derivatives were subsequently produced, with the main focus of this work being to increase selectivity for the non-psychoactive CB 2 receptor. This work led on from an earlier series of sulfamoyl benzamide derivatives for which a patent was filed in 2004. The quinolin-8-yl ester motif of QMPSB led to the discovery of other designer cannabinoids such as PB-22 and BB-22.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1330458185 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.